Multiple Sclerosis
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.
|
25616667 |
2015 |
Multiple Sclerosis
|
0.110 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical study demonstrated infiltration of dimer and polymer IgA1- and A2-positive plasma cells in perivascular spaces, in the parenchyma of MS lesions, and in the adjacent white matter.
|
16099056 |
2005 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urinary MMP-7 level outperformed (C statistic, 0.78) levels of urinary angiotensinogen (C statistic, 0.75), epidermal growth factor (C statistic, 0.75), kidney injury molecule 1 (C statistic, 0.68), and serum galactose-deficient IgA1 (C statistic, 0.59) for predicting IgAN progression.
|
31606236 |
2020 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
With this as background, we investigated how TLR9 activation in IgA secreting cells results in overproduction of nephritogenic IgA in the IgAN-prone ddY mouse and in human IgA1-secreting cells.
|
31748116 |
2020 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Next, we evaluated the IgA1 O-glycan structure of serum IgA from IgAN recipients (n = 26), IgAD donors (n = 17), and non-IgAD helthy donors (n = 27) using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS).
|
30553446 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunoglobulin A nephropathy (IgAN) is considered as mesangiopathy since it initiates in the mesangium; however, other glomerular components are involved and the glomerular capillary wall offers the first contact to circulating macromolecular IgA1.
|
31755918 |
2019 |
IGA Glomerulonephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Median serum Gd-IgA1 levels were significantly higher in IgAN patients [13135.6(2723.3,59603.8)ng/ml] compared to those with non IgA glomerular disease [4954.8(892.9,18256.2) ng/ml] and healthy controls [6299.5(1993.2,19256) ng/ml] and this was observed even after log transformation and adjustment for age and gender(p<0.0001).
|
30917188 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
ELL2 Is Downregulated and Associated with Galactose-Deficient IgA1 in IgA Nephropathy.
|
31275443 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IgA1 frequency in the blood of IgAN patients is significantly higher than that in other Nephropathy (NIgAN) patients and healthy control.
|
30385082 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study points to a new regulatory mechanism of IgAN that can explain the aberrant glycosylation of IgA1.
|
31057023 |
2019 |
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Many studies have demonstrated that galactose-deficient IgA1 (Gd-IgA1) in the IgA1 hinge region is associated with the development and also progression of primary IgAN.
|
31377786 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data support an essential role of the gut microbiota in the generation of mucosa-derived nephrotoxic IgA1 and in IgAN development, opening new avenues for therapeutic approaches in this disease.
|
30462346 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most mesangial IgA1 in human IgAN has a hypogalactosylated hinge region, but it is unclear whether this is required for IgA deposition.
|
31227634 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified and demonstrated that GM130 plays an important role in IgA1 O-glycans deficiency in IgAN patients, by negatively regulating C1GALT1 expression.
|
30917363 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mesangial Gd-IgA1 was positive in IgAN but negative in the normal renal tissue adjacent to neoplasm.
|
31574506 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression.
|
30794576 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, urinary Gd-IgA1 may represent a disease-specific biomarker for IgAN.
|
29740706 |
2019 |
IGA Glomerulonephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum levels of total IgA1 were elevated in IgAN patients compared to healthy subjects.
|
31354895 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Podocytes were incubated with serum containing dys-glycosylated IgA1 protein isolated from IgAN patients.
|
31796125 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both ABO blood group antigens and pathogenic immunoglobulin A1 (IgA1) in patients with IgA nephropathy (IgAN) are influenced by modifications of N-acetylgalactosamine and galactose.
|
31603230 |
2019 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum levels of galactose deficient (Gd)-IgA1 and Gd-IgA1-specific antibodies are elevated in most IgA nephropathy patients.
|
30298660 |
2018 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our study strongly suggests that IgAN and IgA-VN have a shared feature regarding galactose-deficient IgA1-oriented pathogenesis.
|
29329643 |
2018 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, our data suggest that IgG is the predominant isotype of Gd-IgA1-specific autoantibodies in IgA nephropathy.
|
29324897 |
2018 |
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assay for galactose-deficient IgA1 enables mechanistic studies with primary cells from IgA nephropathy patients.
|
30091383 |
2018 |
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The prednisone therapy reduces overall aberrancy in IgA1 O-glycosylation in IgA nephropathy patients, but the measurement of IgA1 parameters does not allow us to predict the prednisone therapy outcome in individual patients.
|
29529610 |
2018 |